Skip to main content

Table 3 DVH constraints for OAR [23]

From: Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

Organ

Parameter

Dose-Volume Constraints

Spinal cord PRV

D Max 0.1 cc

0.1 cc < 18Gy

Kidney

Maximum dose/volume

Dose > 200 cc

If total kidney volume < 200 cc or treating adrenal lesion ensure contralateral kidney dose kept to minimum

< 16Gy

Heart

D max 0.5 cc

<24Gy

Small Bowel

D max 0.5 cc

D 5 cc

< 22.2Gy

< 16.5Gy

Rectum

D max 0.5 cc

< 28.2Gy

Stomach

D max 0.5 cc

D 10 cc

< 22.2Gy

< 16.5Gy

Skin

D max 0.1 cc

D 10 cc

<33Gy

<20Gy

Lungs - GTV

V20Gy

V12.5Gy

< 10%

< 15%

Liver

D > 700 cc

<15Gy

Large Bowel

D max 0.5 cc

< 28.2Gy